• John P O’ConnorBEC, MAICD

    Chairman & Non-Executive Director

    Mr John O’Connor has over 30 year’s experience in the financial industry and was appointed to the novogen board in may 2012. He has held numerous management roles as a fund manager and stockbroker in the UK, US and Australia and also a partnership in a securities business. He has been a consultant to several biotech companies, including Novogen Limited and Marshall Edwards Inc., assisting with fundraising.

    Mr O’Connor served on the Board of Lonsec Securities, a Zurich Insurance owned business, for several years.

  • Bryce Carmine

    Deputy Chairman & Non-Executive Director

    Bryce Carmine spent 36 years working for Eli Lilly & Co. and retired as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines. Prior to this he lead the Global Pharmaceutical Sales and Marketing and was a member of the company’s executive committee.

    Mr Carmine previously held a series of product development portfolio leadership roles culminating when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Eli Lilly.

    During his career with Lilly Bryce held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ & General Manager of a JV for Lilly in Seoul, Korea.

  • Steven CoffeyCA

    Non-Executive Director

    Mr Steven Coffey is a Chartered Accountant, having spent his career in public practice since graduating from NSW University in 1983. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993.

    Mr Coffey is a registered company auditor and audits a number of large private companies as well as not for profit entities. He has previously served on the board of an Australian listed public company and is currently a board member of private family foundation.

  • Ian M PhillipsMNZM

    Non-Executive Director

    Ian M Phillips, MNZM has been involved with International Banking, global financial markets and Corporate Finance for over 30 years having worked in New York (20 years plus), London (5), Singapore (6 months), Sydney (5) and Wellington(4)

    Mr Phillips is President of KUMARA, Chairman of NNP, Deputy Chairman of the American Australian Association immediate past President of the American Friends of the NGA, Chairman of ANZA, an Advisory Board of the US-NZ Council and a Board member of the American friends of Christchurch.

    Mr Phillips studied at Otago University, University of Colorado and London School of economics. Mr Phillips holds dual citizenship USA & NZ. In 2013 was awarded the NZ Order of Merit

  • Iain RossB.SC (HONS), C.DIR

    Non-Executive Director

    Mr Iain Ross is an experienced multinational pharmaceutical and biotechnology executive and is currently Chairman of e-Therapeutics plc (LSE: ETX); Premier veterinary Group plc (lse:pvG) and biomer technology limited. He is also a nonexecutive director of ASX-listed companies Anatara Lifesciences Ltd and Benetic biopharma ltd.

    During his career, Mr Ross has held senior positions at multinational companies, Sandoz AG, Hoffman La Roche, and Celltech Group PLC and been a Chairman, CEO and Director of several biotech companies. He is a qualified Chartered Director and Vice Chairman of the Council of Royal Holloway, London University

  • Dr James GarnerMA, MBA, MBBS, BSC (HONS)

    Chief Executive Officer & Executive Director

    Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation.

    Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Novogen in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore

SITE BY SPATIAL DESIGN